It is a link for moving within the page.

  1. HOME
  2. About Otsuka
  3. News Releases
  4. 2015
  5. Otsuka and Bristol-Myers Squibb Announce a Change in Contract Regarding Collaboration in Japan in the Oncology Therapy Area

March 2, 2015

Otsuka Pharmaceutical Co., Ltd.
Bristol-Myers K.K.

Pharmaceuticals

Otsuka and Bristol-Myers Squibb Announce a Change in Contract Regarding Collaboration in Japan in the Oncology Therapy Area

Otsuka Pharmaceutical Co., Ltd. and the U.S.-based company Bristol-Myers Squibb have agreed to end the co-promotion arrangements for the drug SPRYCEL® (generic name: dasatinib) in Japan, effective from February 27, 2015.

Otsuka and Bristol-Myers Squibb established a global contract in April 2009 in the area of hematological cancers and have been co-promoting SPRYCEL® for the treatment of chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia in Japan since January 2011. Bristol-Myers K.K. continues to promote SPRYCEL® in Japan

Otsuka Pharmaceutical will continue to receive a specified collaboration fee for SPRYCEL net sales in the U.S., Europe*, and Japan. There will be no decrease or other change in terms for the collaboration fee Otsuka Pharmaceutical receives as a result of the termination of co-promotion in Japan.

This change to the agreement is specific to Japan and independent of Bristol-Myers Squibb's partnership with Otsuka in the U.S. and Europe.


Information in this news release was current as of the original release date.

Latest Pharmaceutical Business related News Releases

Most Recent Releases